Figure 1.

Increased cell surface S100A8/A9 in patients with active disease compared with inactive disease and healthy controls. The cell surface S100A8/A9 was determined by flow cytometry on A) CD14⁺⁺CD16⁺, B) CD14⁺⁺CD16^-, C) CD3⁺, D) CD19⁺, E) CD16+ PMNs, F) BDCA-1⁺ and G) BDCA-2⁺ cells. The expression is defined as the mean fluorescence index (MFI) ratio between the S100A8/A9 antibody and its control isotype antibody in each experiment. The line represents the median-value. Active disease was defined as SLEDAI > 4 (SLE active).